Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Covered Calls

Teva Pharmaceutical Industries (TEVA) is a global leader in generic and specialty medicines. Headquartered in Israel, it operates one of the world's largest integrated manufacturing and delivery networks, supplying approximately 3,600 products daily. Teva balances its foundational strength in affordable generic drugs with a growing portfolio of innovative specialty medicines focused on central nervous system (CNS) disorders, respiratory conditions, and oncology.

You can sell covered calls on Teva Pharmaceutical Industries Limited American Depositary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for TEVA (prices last updated Tue 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Teva operates through a dual-pillar business model: Generic Medicines and Innovative Medicines. Its generics division provides high-quality, cost-effective alternatives to branded drugs, leveraging immense economies of scale to maintain market leadership. The innovative medicines division focuses on high-value therapies—such as AUSTEDO (for movement disorders), AJOVY (for migraine prevention), and UZEDY (for schizophrenia)—which serve as the primary engines for its "Pivot to Growth" strategy.

A critical component of Teva's operations is its robust Active Pharmaceutical Ingredient (API) business and its U.S.-based distribution arm, Anda. By vertically integrating the production of key ingredients and managing a sophisticated distribution network, Teva optimizes supply chain resilience and captures value across the pharmaceutical lifecycle. The company is currently focused on deleveraging its balance sheet and advancing a pipeline of complex generics and biosimilars to sustain long-term growth in a competitive global market.

Competitive Landscape

Teva faces intense competition from both large-cap "Big Pharma" giants and specialized generic producers. Key optionable competitors include:

1. Viatris (VTRS): Formed from the merger of Mylan and Upjohn, Viatris is a direct rival in the generic and off-patent branded medicine space. It competes head-to-head with Teva on manufacturing scale and global pricing power.
2. GSK (GSK): A global pharmaceutical giant that competes in specialty therapeutic areas. While GSK maintains a much larger footprint in vaccines and immunology, its specialty medicines portfolio overlaps with Teva’s, creating competition in high-value innovative markets.
3. Novartis (NVS): Through its Sandoz division (though now independent, remains a key industry benchmark) and its broader innovative portfolio, Novartis represents a high-bar standard for both generic volume and premium specialty innovation, frequently challenging Teva for market share in complex biosimilars.

Strategic Outlook and Innovation

Teva is executing its "Pivot to Growth" strategy, which prioritizes the scaling of its innovative medicines franchise to exceed $5 billion in revenue by 2030. Management is focused on operational efficiency, debt reduction, and maximizing the performance of its existing specialty blockbusters. By balancing its reliable cash flow from the generics business with selective R&D investment in high-impact specialty assets, Teva aims to transform into a biopharmaceutical leader.

Looking ahead, the company continues to navigate the complexities of international regulatory environments and patent cliffs. By maintaining a disciplined approach to capital allocation and focusing on complex generics and biologics where barriers to entry are higher, Teva intends to sustain its competitive edge and deliver value in the evolving global pharmaceutical landscape.

Want more examples? TERN Covered Calls | TEX Covered Calls